A clinical trial study (NCT01203917) aimed to assess the efficacy and tolerability of gefitinib as first-line therapy for common EGFR mutations (19del, L858R, T790M) positive patients in stage III/IV NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.